Why partner with Santen?

The Santen global network includes three clinical development centers and five world-class manufacturing sites. Our fully integrated range of capabilities allows for the accelerated delivery of a wide range of high-quality, innovative new ophthalmic drugs.

Our commitment to creating a robust product pipeline that will generate a steady flow of marketable new products is exemplified by our 2009 R&D budget of more than ¥18 billion and by a number of compounds currently under development.

Net Sales

With net sales of over ¥101 billion, Santen's position as one of the premier ophthalmic pharmaceutical companies remains unchallenged. In order to accomplish our mission of fulfilling unmet medical needs through the development of innovative new ophthalmic medicines, we fully intend to engage with other leading-edge organizations in order to accomplish the goals we have set for the future.

By combining our global expertise with partners of like-minded vision, we will contribute to the health and quality of life of patients, their loved ones, and society as a whole.

A history of successful collaborations

Throughout its history Santen has strengthened its own organization through cooperative alliances. A formidable relationship with Allergan, Inc. in 1973, continued the growth of Santen's global network of partnerships which includes pharmaceutical companies, universities, research centers and venture businesses.